Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.52 |
| ▸ | MME | P08473 | 5/20 | 0.51 |
| ▸ | BACE1 | P56817 | 5/20 | 0.51 |
| ▸ | GNPAT | O15228 | 1/20 | 0.47 |
| ▸ | ACE | P12821 | 2/20 | 0.47 |
| ▸ | CPA1 | P15085 | 2/20 | 0.47 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.47 |
| ▸ | ECE1 | P42892 | 1/20 | 0.47 |
| ▸ | CTSD | P07339 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30272495 | 0.95 | GNPAT (0.53) | NAALAD2MMEBACE1GNPATECE1 | |
| SCHEMBL30903452 | 0.93 | BACE1 (0.57) | NAALAD2MMEBACE1CTSD | |
| SCHEMBL29652313 | 0.93 | NAALAD2 (0.54) | NAALAD2MMEBACE1GNPATACE | |
| SCHEMBL29531743 | 0.91 | NAALAD2 (0.64) | NAALAD2MMEBACE1CTSD | |
| SCHEMBL30688829 | 0.91 | GNPAT (0.54) | NAALAD2MMEBACE1GNPATACE | |
| SCHEMBL31672252 | 0.91 | GNPAT (0.54) | NAALAD2MMEBACE1GNPATACE | |
| SCHEMBL31474554 | 0.91 | BACE1 (0.56) | NAALAD2MMEBACE1GNPATCTSD | |
| SCHEMBL29733676 | 0.91 | NAALAD2 (0.64) | NAALAD2MMEBACE1CTSD | |
| SCHEMBL30123399 | 0.90 | MME (0.51) | NAALAD2MMEBACE1GNPATACE | |
| SCHEMBL31720880 | 0.89 | BACE1 (0.61) | NAALAD2BACE1CTSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250074942-A1 | COMPOSITIONS AND METHODS FOR COVALENT PEPTIDE-BASED MODULATORS OF HLA-E | CALICO LIFE SCIENCES LLC (US) | 2025-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250074942-A1 | COMPOSITIONS AND METHODS FOR COVALENT PEPTIDE-BASED MODULATORS OF HLA-E | MICA, CD74, HLA-DRB1 | NAALAD2 1237/4885MME 130/4885BACE1 2095/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.